Great announcement!
Certainly much better than if it was rejected haha!
It will be very interesting if the IER has to change now. I don’t logically see how it can recommend that it’s in our best interest to sell at 14.6 cents when they didn’t have this knowledge at the time of writing and can only add value to the company.
Interesting times ahead still.
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx, page-19
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
